Breast Cancer
Antitumor activity reported for ABI-007 in patients resistant to taxane
Published in Women's Health Weekly, July 3rd, 2003
At the recent American Society of Clinical Oncology (ASCO) meeting, American Pharmaceutical Partners, Inc., (APPX) said investigators reported on the early findings in a phase II metastatic breast cancer trial of ABI-007, a novel Cremophor-free protein engineered nanoparticle paclitaxel, and results of intra-arterial ABI-007 in phase II trial in head and neck cancer patients as well as patients with cancers of the pelvis
Patients were eligible to enter the phase II metastatic breast cancer trial if they had shown ongoing growth of their tumor even after receiving either Taxol and/or Taxotere therapy. In this refractory or resistant population, ABI-007 was administered...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Inherited vulnerability to hormones of puberty may be a cause of disease - Stroke
Women's first stroke more severe and disabling than men's - Endometrial Angiogenesis
ETS-1 expression is related to angiogenesis during the menstrual cycle - Endometriosis
Peritoneal fluid has lower amounts of some proteins and increased IL-10 - Stroke
Low-dose 'Pill' may have less stroke risk for young women - Women's Health
Primary ovarian cancer spheroids host replicative adenovirus targeting integrin - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
